FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3200339764> ?p ?o ?g. }

• W3200339764 endingPage "e481" @default.
• W3200339764 startingPage "e473" @default.
• W3200339764 abstract "Severe acute respiratory syndrome coronavirus 2 infection may be associated with a prothrombotic state, predisposing patients for a progressive disease course. We investigated whether rivaroxaban, a direct oral anticoagulant factor Xa inhibitor, would reduce coronavirus disease 2019 (COVID-19) progression.Adults (N = 497) with mild COVID-19 symptoms and at high risk for COVID-19 progression based on age, body mass index, or comorbidity were randomized 1:1 to either daily oral rivaroxaban 10 mg (N = 246) or placebo equivalent (N = 251) for 21 days and followed to day 35. Primary end points were safety and progression. Absolute difference in progression risk was assessed using a stratified Miettinen and Nurminen method.The study was terminated after 497 of the target 600 participants were enrolled due to a prespecified interim analysis of the first 200 participants that crossed the futility boundary for the primary efficacy end point in the intent-to-treat population. Enrollees were 85% aged <65 years; 60% female; 27% Hispanic, Black, or other minorities; and 69% with ≥2 comorbidities. Rivaroxaban was well tolerated. Disease progression rates were 46 of 222 (20.7%) in rivaroxaban vs 44 of 222 (19.8%) in placebo groups, with a risk difference of -1.0 (95% confidence interval, -6.4 to 8.4; P = .78).We did not demonstrate an impact of rivaroxaban on disease progression in high-risk adults with mild COVID-19. There remains a critical public health gap in identifying scalable effective therapies for high-risk people in the outpatient setting to prevent COVID-19 progression." @default.
• W3200339764 created "2021-09-27" @default.
• W3200339764 creator A5000124441 @default.
• W3200339764 creator A5007397579 @default.
• W3200339764 creator A5034350124 @default.
• W3200339764 creator A5035211563 @default.
• W3200339764 creator A5035603988 @default.
• W3200339764 creator A5054253267 @default.
• W3200339764 creator A5056809600 @default.
• W3200339764 creator A5061857879 @default.
• W3200339764 creator A5074116844 @default.
• W3200339764 creator A5080589348 @default.
• W3200339764 creator A5082377935 @default.
• W3200339764 date "2021-09-15" @default.
• W3200339764 modified "2023-10-16" @default.
• W3200339764 title "Randomized Study of Rivaroxaban vs Placebo on Disease Progression and Symptoms Resolution in High-Risk Adults With Mild Coronavirus Disease 2019" @default.
• W3200339764 cites W2122633654 @default.
• W3200339764 cites W2162499932 @default.
• W3200339764 cites W3011976215 @default.
• W3200339764 cites W3016595631 @default.
• W3200339764 cites W3017326650 @default.
• W3200339764 cites W3020995110 @default.
• W3200339764 cites W3021393314 @default.
• W3200339764 cites W3022187628 @default.
• W3200339764 cites W3025754925 @default.
• W3200339764 cites W3027630905 @default.
• W3200339764 cites W3027918021 @default.
• W3200339764 cites W3028989873 @default.
• W3200339764 cites W3043308024 @default.
• W3200339764 cites W3095016916 @default.
• W3200339764 cites W3108315781 @default.
• W3200339764 cites W3108572624 @default.
• W3200339764 cites W3125580289 @default.
• W3200339764 cites W3138214175 @default.
• W3200339764 cites W3138406303 @default.
• W3200339764 cites W3156297617 @default.
• W3200339764 cites W3172155398 @default.
• W3200339764 doi "https://doi.org/10.1093/cid/ciab813" @default.
• W3200339764 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8522357" @default.
• W3200339764 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34523673" @default.
• W3200339764 hasPublicationYear "2021" @default.
• W3200339764 type Work @default.
• W3200339764 sameAs 3200339764 @default.
• W3200339764 citedByCount "28" @default.
• W3200339764 countsByYear W32003397642022 @default.
• W3200339764 countsByYear W32003397642023 @default.
• W3200339764 crossrefType "journal-article" @default.
• W3200339764 hasAuthorship W3200339764A5000124441 @default.
• W3200339764 hasAuthorship W3200339764A5007397579 @default.
• W3200339764 hasAuthorship W3200339764A5034350124 @default.
• W3200339764 hasAuthorship W3200339764A5035211563 @default.
• W3200339764 hasAuthorship W3200339764A5035603988 @default.
• W3200339764 hasAuthorship W3200339764A5054253267 @default.
• W3200339764 hasAuthorship W3200339764A5056809600 @default.
• W3200339764 hasAuthorship W3200339764A5061857879 @default.
• W3200339764 hasAuthorship W3200339764A5074116844 @default.
• W3200339764 hasAuthorship W3200339764A5080589348 @default.
• W3200339764 hasAuthorship W3200339764A5082377935 @default.
• W3200339764 hasBestOaLocation W32003397641 @default.
• W3200339764 hasConcept C126322002 @default.
• W3200339764 hasConcept C141071460 @default.
• W3200339764 hasConcept C142724271 @default.
• W3200339764 hasConcept C168563851 @default.
• W3200339764 hasConcept C203092338 @default.
• W3200339764 hasConcept C204787440 @default.
• W3200339764 hasConcept C27081682 @default.
• W3200339764 hasConcept C2776301958 @default.
• W3200339764 hasConcept C2778661090 @default.
• W3200339764 hasConcept C2779123688 @default.
• W3200339764 hasConcept C2779134260 @default.
• W3200339764 hasConcept C2779159551 @default.
• W3200339764 hasConcept C2779161974 @default.
• W3200339764 hasConcept C3008058167 @default.
• W3200339764 hasConcept C524204448 @default.
• W3200339764 hasConcept C71924100 @default.
• W3200339764 hasConceptScore W3200339764C126322002 @default.
• W3200339764 hasConceptScore W3200339764C141071460 @default.
• W3200339764 hasConceptScore W3200339764C142724271 @default.
• W3200339764 hasConceptScore W3200339764C168563851 @default.
• W3200339764 hasConceptScore W3200339764C203092338 @default.
• W3200339764 hasConceptScore W3200339764C204787440 @default.
• W3200339764 hasConceptScore W3200339764C27081682 @default.
• W3200339764 hasConceptScore W3200339764C2776301958 @default.
• W3200339764 hasConceptScore W3200339764C2778661090 @default.
• W3200339764 hasConceptScore W3200339764C2779123688 @default.
• W3200339764 hasConceptScore W3200339764C2779134260 @default.
• W3200339764 hasConceptScore W3200339764C2779159551 @default.
• W3200339764 hasConceptScore W3200339764C2779161974 @default.
• W3200339764 hasConceptScore W3200339764C3008058167 @default.
• W3200339764 hasConceptScore W3200339764C524204448 @default.
• W3200339764 hasConceptScore W3200339764C71924100 @default.
• W3200339764 hasIssue "1" @default.
• W3200339764 hasLocation W32003397641 @default.
• W3200339764 hasLocation W32003397642 @default.
• W3200339764 hasLocation W32003397643 @default.
• W3200339764 hasOpenAccess W3200339764 @default.
• W3200339764 hasPrimaryLocation W32003397641 @default.
• W3200339764 hasRelatedWork W2047967234 @default.

• next